Chiron Injunction Over HCV Immunoassays
Chiron has been granted a preliminary cross-border injunction against Organon and United Biomedical Inc relating to the manufacture, sale and distribution of hepatitis C virus immunoassays in Europe. UBI manufactures the assays in the USA for sale by Organon in Europe.
The injunction prevents Organon and UBI from manufacturing, distributing or selling HCV tests in Austria, Belgium, France, Germany, Italy, Liechtenstein, Luxembourg, the Netherlands, Spain, Sweden and Switzerland. Organon is also required to recall all its HCV kits in the Netherlands and deliver to Chiron a list of its customers in that country within 14 days. Chiron licenses its HCV immunoassay technology to Abbott Laboratories and Pasteur Sanofi Diagnostics.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze